PSYENCE BIOMEDICAL Business Summary

Psyence Biomedical Ltd. (PBM) operates as a vertically integrated biopharmaceutical company specializing in the development and commercialization of nature-derived (non-synthetic) psychedelic medicines. The company’s business model is centered on a clinical-stage pipeline targeting unmet mental health needs, primarily through its flagship Phase IIb clinical trial in Australia evaluating psilocybin-assisted psychotherapy for Adjustment Disorder in palliative care. PBM generates value through three primary segments: Clinical Development, which manages its proprietary drug candidates; Manufacturing and Supply Chain, bolstered by a strategic 49.98% equity stake in PsyLabs to secure GMP-compliant psilocybin and ibogaine; and Longevity Science, a niche division focused on the neurobiological dimensions of aging. In the competitive landscape, PBM contends with synthetic-focused peers such as Compass Pathways (CMPS), Cybin Inc. (CYBN), and GH Research (GHRS). PBM distinguishes itself as the only Nasdaq-listed entity exclusively dedicated to nature-derived compounds and the convergence of psychedelic therapeutics with longevity science. The leadership team is anchored by Co-Founder and CEO Jody Aufrichtig, a Chartered Accountant and seasoned entrepreneur who previously led Canopy Growth’s African operations. He is supported by CFO Warwick Corden-Lloyd, whose pedigree includes serving as VP of Operations and Finance for Canopy Growth Africa and Head of Financial Accounting at Capitec Bank. Technical and clinical strategy is directed by Dr. Neil Maresky, the Global Head of Clinical Development and former CEO, who brings over 17 years of pharmaceutical experience from senior roles at AstraZeneca, Wyeth, and Novartis. The company’s governance and strategic direction are further influenced by a Scientific Advisory Board featuring experts like Dr. Dan J. Stein and Dr. Albert P. Garcia-Romeu of Johns Hopkins. Following a major share-for-share exchange in early 2026, PsyLabs has emerged as a dominant institutional investor, holding nearly half of the company’s outstanding shares and ensuring a tightly aligned supply-to-clinic ecosystem.